Yasukazu Nakanishi

Yasukazu Nakanishi

Auto-generated profile, based on publicly available information

Yasukazu Nakanishi

Department of Urology National Cancer Center Hospital East Kashiwa Chiba Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
KTKosuke Takemura
Kosuke Takemura
Hiroshi FukushimaHiroshi Fukushima
Hiroshi Fukushima
MIMasaya Ito
Masaya Ito
MKMadoka Kataoka
Madoka Kataoka
YNYasukazu Nakanishi
Yasukazu Nakanishi
Fumitaka KogaFumitaka Koga
Fumitaka Koga

23 March 2021 in IJU Case Reports
Verified
Journal Article
Open access
PDF file
SYShugo Yajima
Shugo Yajima
YNYasukazu Nakanishi
Yasukazu Nakanishi
SMShunya Matsumoto
Shunya Matsumoto
KTKenji Tanabe
Kenji Tanabe
MSMasato Sugano
Masato Sugano
HMHitoshi Masuda
Hitoshi Masuda
Introduction: We present a case of cystitis, which was considered to be an immune‐related adverse event associated with nivolumab administration.Case presentation: A 47‐year‐old man suffered from sudden onset urinary symptoms after 18 cycles of nivolumab treatment for stage IV pulmonary adenocarcinoma. Urine culture and urine cytology were both negative. The symptoms were inferred to be related to nivolumab administration, and a bladder biopsy under spinal anesthesia was performed. The histopathological examination showed the evidence of allergic‐related cystitis. We planned to administer corticosteroids, but the urinary symptoms disappeared after the bladder biopsy. Nivolumab treatment was continued without recurrent bladder symptoms.Conclusion: We reported a case of cystitis after treatment with nivolumab, which served as a reminder to consider the possibility of immune‐related adverse events as a potential cause for any symptoms that develop during treatment with immuno‐oncology drugs.

1 December 2014 in International braz j urol
Verified
Journal Article
Open access
PDF file
JIJunichiro Ishioka
Junichiro Ishioka
KKKazunori Kihara
Kazunori Kihara
SHSaori Higuchi
Saori Higuchi
TNTakayuki Nakayama
Takayuki Nakayama
HTHideki TAKESHITA
Hideki TAKESHITA
Yasuhisa FujiiYasuhisa Fujii
Yasuhisa Fujii
Key words: Urinary Tract; Ureteroscopy; Natural Orifice Endoscopic Surgery; Video-Assisted Surgery

26 August 2022 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
SYShugo Yajima
Shugo Yajima
YNYasukazu Nakanishi
Yasukazu Nakanishi
RYRikuto Yasujima
Rikuto Yasujima
KHKouhei Hirose
Kouhei Hirose
KSKen Sekiya
Ken Sekiya
HMHitoshi Masuda
Hitoshi Masuda

1 September 2022 in Urology Research and Practice
Verified
Journal Article
Open access
KTKenji Tanabe
Kenji Tanabe
YNYasukazu Nakanishi
Yasukazu Nakanishi
YUYosuke Umino
Yosuke Umino
NONaoya Ookubo
Naoya Ookubo
MKMadoka Kataoka
Madoka Kataoka
HMHitoshi Masuda
Hitoshi Masuda
Objective: To improve perioperative outcomes, robot-assisted radical cystectomy has gained increasing interest. This study aimed to assess the detailed perioperative complications of robot-assisted radical cystectomy in elderly aged ≥80 years and compare them with those of non-elderly. Material and methods: We retrospectively analyzed the clinical features of 74 patients who underwent robotassisted radical cystectomy for bladder cancer between September 2018 and September 2021. Perioperative complication was classified by the Clavien–Dindo classification and organ system-based categories. We assessed the relationship between age or Charlson comorbidity index score (≥3 or <3) and the incidence of perioperative complication or rehospitalization rate within 90 days postoperatively. Results: Of the 74 patients, perioperative complication of all grades and grade ≥IIIa occurred in 54 (73%) and 15 (20%) patients, respectively. The postoperative rehospitalization rate was 20%, and the perioperative mortality rate was 0%. Elderly (n = 20) showed no difference in the incidence of perioperative complication of all grades or grade ≥IIIa compared with non-elderly, and no organ system-based category had a higher incidence in elderly than that in non-elderly. Gastrointestinal tract-related perioperative complication incidence was higher in non-elderly and those with Charlson comorbidity index ≥3 (P = .044, .039, respectively); cardi ovasc ular- relat ed perioperative complication incidence was higher in those with Charlson comorbidity index ≥ 3 (P = .0068). Conclusion: The incidence perioperative complication of robot-assisted radical cystectomy in elderly was not different from those in non-elderly, suggesting that robot-assisted radical cystectomy may be an option for the treatment of bladder cancer in elderly as well as non-elderly. Cite this article as: Tanabe K, Nakanishi Y, Umino Y, et al. Validity and safety of robot-assisted laparoscopic radical cystectomy for the elderly: Results of perioperative outcomes in patients aged ≥80 years. Turk J Urol. 2022;48(5):322-330.

7 September 2022 in BMC Urology
Verified
Journal Article
Open access
PDF file
YNYasukazu Nakanishi
Yasukazu Nakanishi
SMShunya Matsumoto
Shunya Matsumoto
NONaoya Okubo
Naoya Okubo
KTKenji Tanabe
Kenji Tanabe
MKMadoka Kataoka
Madoka Kataoka
HMHitoshi Masuda
Hitoshi Masuda
We assess whether short-term recovery of urinary incontinence following robot-assisted laparoscopic radical prostatectomy (RARP) is associated with postoperative membranous urethral length (MUL) and position of vesico-urethral anastomosis (PVUA). Clinical variables including PVUA and pre-and postoperative MUL were evaluated in 251 patients who underwent RARP from August 2019 to February 2021. Continence recovery was defined as no pad or one security liner per day assessed by patient interview at least 6 months follow-up. Univariate and multivariate logistic regression analyses were used to assess variables associated with continence recovery at 3 months after the operation. Continence recovery rates at 3 and 6 months were 75% and 84%, respectively. Lower BMI (< 25 kg/m2) (p = 0.040), longer preoperative MUL (≥ 9.5 mm) (p = 0.013), longer postoperative MUL (≥ 9 mm) (p < 0.001), higher PVUA (< 14.5 mm) (p = 0.019) and shorter operating time (< 170 min) (p = 0.013) were significantly associated with continence recovery at 3 months in univariate analysis. Multivariate analysis revealed that postoperative MUL (OR 3.75, 95% CI 1.90–7.40, p < 0.001) and higher PVUA (OR 2.02, 95% CI 1.07–3.82, p = 0.032) were independent factors for continence recovery. Patients were divided into 3 groups based on the multivariate analysis, with urinary continence recovery rates found to have increased in turn with rates of 43.7% versus 68.2% versus 85.0% (p < 0.001) at 3 months. PVUA and postoperative MUL were significant factors for short-term continence recovery. Preservation of urethral length might contribute to continence recovery after RARP.